Skip to content
MedsAcross

Medicine

Dicloxacillin 250 mg capsule

Available on requestPrescription onlyUS FDAGeneric name

Dicloxacillin 250 mg capsule is a generic prescription medicine for oral use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F).

Key facts

Active ingredient (INN)
Dicloxacillin
Brand
Sold under the generic name
Strength
250 mg
Dosage form
Capsule
Route
Oral
Packs
100 capsules, 6 capsules, 10 capsules and 4 more
Manufacturers
Aurobindo PharmaIndiaPD-Rx PharmaceuticalsTeva Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
J01CF01 Dicloxacillin
HS code (indicative)
3004.10Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 September 1990
Identifiers
RxCUI 197595, 197596DailyMed set ID 9e2bbe03-44cb-45d1-acdb-b61d9016055e, c17cd62d-ff5d-47ba-8673-3346c7f2365f, 8478f242-c715-4984-ac1d-dc79dc28665e +1NDC 55289-592, 43063-180, 0093-3123 +1Application ANDA062286, ANDA216845

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
100 capsule in 1 bottle59651-565-01Aurobindo PharmaIndia23 September 2022
100 capsule in 1 bottle0093-3123-01Teva Pharmaceuticals30 September 1990
6 capsule in 1 bottle43063-180-06PD-Rx Pharmaceuticals11 August 2009
10 capsule in 1 bottle, plastic55289-592-10PD-Rx Pharmaceuticals20 January 2011
20 capsule in 1 bottle, plastic55289-592-20PD-Rx Pharmaceuticals20 January 2011
28 capsule in 1 bottle, plastic55289-592-28PD-Rx Pharmaceuticals20 January 2011
40 capsule in 1 bottle, plastic55289-592-40PD-Rx Pharmaceuticals20 January 2011

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 22 April 1968Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Dicloxacillin

Clinical summary

Dicloxacillin is a penicillin-class antibacterial indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It is available as capsules for oral use. MedsAcross supplies Dicloxacillin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Dicloxacillin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Dicloxacillin 250 mg capsule for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.